Patient characteristics, acute GvHD and outcome
| UPN . | Age . | Sex . | Disease, Disease state . | Stem cell source . | Conditioning . | GvHD prophylaxis . | Grade of acute GvHD skin/liver/GIT/OA . | Outcome . |
|---|---|---|---|---|---|---|---|---|
| 282 | 33 | M | ALL, 2 CR | PBSC, MUD | TBI/Mel | ATG, TCD | 3/2/4/4 | Dead, day + 99, aGvHD |
| 292 | 33 | M | AML, 1 rel | PBSC, HLA-id fam | TBI/CTX | ATG, CSA, MMF | 3/3/4/4 | Dead, day + 185, aGvHD |
| 299 | 39 | M | ALL Ph+, 1 CR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 2/0/1/2 | Alive, day + 915 |
| 307 | 57 | M | ALL Ph+, 3 rel | PBSC, MUD | Flu/Mel | ATG, CSA, MMF | 3/2/2/3 | Dead, day + 295, relapse |
| 308 | 53 | F | ALL Ph+, RD | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 3/2/4/4 | Dead, day + 80, aGvHD |
| 310 | 25 | F | ALL Ph+, 1 CR | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 3/0/3/3 | Dead, day + 208, interstitial pneumonitis |
| 248-2* | 35 | M | ALL Ph+, 3 rel | PBSC, HLA-id fam | Flu/Mel | ATG, CSA | 2/2/4/4 | Dead, day + 115, aGvHD |
| 312 | 57 | F | CML, AP | BM, MUD | Flu/Bu | ATG, CSA, MMF | 3/0/1/2 | Alive, day + 756 |
| 313 | 25 | M | ALL Ph+, 1 CR | BM, MUD | TBI/CTX | ATG, CSA, MMF | 3/0/0/2 | Alive, day + 748 |
| 314 | 60 | M | ALL Ph+, 1 CR | PBSC, HLA-id fam | Flu/Mel | ATG, CSA, MMF | 0/0/0/0 | Dead, day + 46, interstitial pneumonitis |
| 315 | 27 | F | MDS (RAEB-t), PR | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 3/0/3/3 | Dead, day + 76, subarachnoid hemorrhage |
| 316 | 57 | M | ALL Ph+, 2 CR | PBSC, HLA-id fam | Flu/Mel | ATG, CSA, MMF | 2/0/3/3 | Dead, day + 136, relapse |
| 318 | 43 | M | AML, 1 CR | PBSC, MUD | TT/Mel | ATG, CSA, MMF | 0/0/0/0 | Dead, day + 9, haemorrhagic colitis |
| 319 | 50 | M | AML, 1 rel | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 0/0/0/0 | Dead, day + 95,Candida septicemia |
| 320 | 33 | F | AML, 1 rel | PBSC, HLA-id fam | TBI/CTX | ATG, CSA, MMF | 2/0/0/1 | Dead, day + 52, relapse |
| 339 | 44 | F | ALL, 2 CR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 2/0/1/2 | Dead, day + 176, relapse |
| 360 | 42 | F | ALL Ph+, 1 CR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 0/0/0/0 | Alive, day + 342, relapse |
| 370 | 47 | F | ALL Ph+, PR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 1/0/1/2 | Alive, day + 286, relapse |
| 380 | 38 | F | AML, PR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 3/0/0/2 | Alive, day + 200, relapse |
| UPN . | Age . | Sex . | Disease, Disease state . | Stem cell source . | Conditioning . | GvHD prophylaxis . | Grade of acute GvHD skin/liver/GIT/OA . | Outcome . |
|---|---|---|---|---|---|---|---|---|
| 282 | 33 | M | ALL, 2 CR | PBSC, MUD | TBI/Mel | ATG, TCD | 3/2/4/4 | Dead, day + 99, aGvHD |
| 292 | 33 | M | AML, 1 rel | PBSC, HLA-id fam | TBI/CTX | ATG, CSA, MMF | 3/3/4/4 | Dead, day + 185, aGvHD |
| 299 | 39 | M | ALL Ph+, 1 CR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 2/0/1/2 | Alive, day + 915 |
| 307 | 57 | M | ALL Ph+, 3 rel | PBSC, MUD | Flu/Mel | ATG, CSA, MMF | 3/2/2/3 | Dead, day + 295, relapse |
| 308 | 53 | F | ALL Ph+, RD | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 3/2/4/4 | Dead, day + 80, aGvHD |
| 310 | 25 | F | ALL Ph+, 1 CR | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 3/0/3/3 | Dead, day + 208, interstitial pneumonitis |
| 248-2* | 35 | M | ALL Ph+, 3 rel | PBSC, HLA-id fam | Flu/Mel | ATG, CSA | 2/2/4/4 | Dead, day + 115, aGvHD |
| 312 | 57 | F | CML, AP | BM, MUD | Flu/Bu | ATG, CSA, MMF | 3/0/1/2 | Alive, day + 756 |
| 313 | 25 | M | ALL Ph+, 1 CR | BM, MUD | TBI/CTX | ATG, CSA, MMF | 3/0/0/2 | Alive, day + 748 |
| 314 | 60 | M | ALL Ph+, 1 CR | PBSC, HLA-id fam | Flu/Mel | ATG, CSA, MMF | 0/0/0/0 | Dead, day + 46, interstitial pneumonitis |
| 315 | 27 | F | MDS (RAEB-t), PR | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 3/0/3/3 | Dead, day + 76, subarachnoid hemorrhage |
| 316 | 57 | M | ALL Ph+, 2 CR | PBSC, HLA-id fam | Flu/Mel | ATG, CSA, MMF | 2/0/3/3 | Dead, day + 136, relapse |
| 318 | 43 | M | AML, 1 CR | PBSC, MUD | TT/Mel | ATG, CSA, MMF | 0/0/0/0 | Dead, day + 9, haemorrhagic colitis |
| 319 | 50 | M | AML, 1 rel | PBSC, MUD | TBI/CTX | ATG, CSA, MMF | 0/0/0/0 | Dead, day + 95,Candida septicemia |
| 320 | 33 | F | AML, 1 rel | PBSC, HLA-id fam | TBI/CTX | ATG, CSA, MMF | 2/0/0/1 | Dead, day + 52, relapse |
| 339 | 44 | F | ALL, 2 CR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 2/0/1/2 | Dead, day + 176, relapse |
| 360 | 42 | F | ALL Ph+, 1 CR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 0/0/0/0 | Alive, day + 342, relapse |
| 370 | 47 | F | ALL Ph+, PR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 1/0/1/2 | Alive, day + 286, relapse |
| 380 | 38 | F | AML, PR | PBSC, HLA-id fam | TBI/CTX | ATG, TCD | 3/0/0/2 | Alive, day + 200, relapse |
UPN indicates unique patient number; GIT, gastrointestinal tract; OA, overall stage of acute GvHD; ALL, acute lymphoblastic leukemia; CR, complete remission; PBSC, peripheral blood stem cells; MUD, matched unrelated donor; TBI/Mel, 7 × 1.8 Gy + 140 mg/m2melphalan; ATG, antithymocyte globuline (Fresenius) 40 mg/kg; TCD, T-cell depletion (CliniMACS); AML, acute myeloid leukemia; rel, relapse; HLA-id fam, HLA-identical family donor; TBI/CTX, 7 × 1.8 Gy + 120 mg/kg cyclophosphamide; CSA, ciclosporin A; MMF, mycophenolate mofetil; Ph+, Philadelphia chromosome positive; Flu/Mel, 180 mg/m2 fludarabin + 140 mg/m2 melphalan; RD, refractory disease; CML, chronic myeloid leukemia; AP, accelerated phase; BM, bone marrow; Flu/Bu, 180 mg/m2 fludarabin + 8 mg/kg busulfan; MDS, myelodysplastic syndrome; RAEB-t, refractory anemia with excess of blasts in transformation; TT/Mel, 600 mg/m2 thiotepa + 140 mg/m2 melphalan; PR, partial remission.
The “2” indicates that it is the second transplantation for this patient.